A study led by researchers at Queen Mary University of London found two new common genetic variants in 40,000 individuals which significantly affected the degree to which bad cholesterol was lowered during statin treatment. A followup study of a further 22,318 individuals confirmed the findings. One of the identified genetic variants was shown to enhance statin response. In contrast, the second variant, thought to have a role in the uptake of statins by the liver, decreased the effects of the drug. Via Science Daily. Posted November 3, 2014.
Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.
Did you find this article helpful?